4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction

动脉网2025-07-08

4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549546558?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 18:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549546558","market":"us","top_or_hot":-1,"title":"4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction","media":"动脉网","content":"<div>\n<p>4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 18:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0127658192.USD","symbol_name":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b","article_id":"2549546558","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708183324953ab7a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549546558","pubTimestamp":1751970540,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Additionally, 4FRONT-2, the global phase 3 trial of 4D-150 in wet AMD, was initiated in June 2025 ahead of schedule. This study mirrors the design of 4FRONT-1 but will enroll both treatment-nave patients and recently diagnosed, treatment-experienced individuals. Topline results from 4FRONT-2 are expected in the second half of 2027..此外，4D-150用于湿性AMD的全球三期试验4FRONT-2已于2025年6月提前启动。4FRONT-2的初步结果预计将在2027年下半年公布。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU0082616367.USD":"摩根大通美国科技A（dist）","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","BK4573":"虚拟现实","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","GFS":"GLOBALFOUNDRIES Inc.","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4554":"元宇宙及AR概念","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4543":"AI","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4141":"半导体产品","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","BK4529":"IDC概念","BK4575":"芯片概念","LU0056508442.USD":"贝莱德世界科技基金A2","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","BK4566":"资本集团","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK4612":"AI芯片","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","BK4614":"Manus概念股","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0109392836.USD":"富兰克林科技股A","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4605":"半导体精选","BK4588":"碎股","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","AMD":"美国超微公司"},"translate_title":"4DMT Accelerates 4FRONT Phase 3 Project for Wet AMD, Implements Layoff Measures 4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMD":0.9,"GFS":1},"content_text":"4DMT Accelerates 4FRONT Phase 3 Program for Wet AMD, Implements Workforce Reduction4DMT加速湿性AMD的4FRONT第三阶段项目，实施裁员措施July 08, 20252025年7月8日4D Molecular Therapeutics (4DMT) has announced the acceleration of its 4D-150 4FRONT phase 3 clinical program targeting wet age-related macular degeneration (wet AMD) alongside a strategic move to lay off approximately 25% of its workforce. This decision comes as the company sharpens its focus on advancing its late-stage pipeline..4D Molecular Therapeutics (4DMT) 宣布加速其针对湿性年龄相关性黄斑变性（湿性AMD）的4D-150 4FRONT第三阶段临床计划，同时进行战略调整，裁员约25%的员工。这一决定是在公司集中精力推进其后期管线之际作出的。Streamlining Operations to Support Accelerated Timelines简化操作以支持加快的时间表According to 4DMT, the company will streamline operations to help offset additional costs tied to the faster timelines of the 4FRONT clinical trials and biologics license application (BLA) preparation. This transition aligns with the strategy first announced in January 2025, emphasizing a focus on late-stage programs.根据4DMT公司介绍，公司将精简运营，以帮助抵消与4FRONT临床试验和生物制品许可申请（BLA）准备加快时间表相关的额外成本。此次转型符合公司于2025年1月首次宣布的战略，重点放在后期项目上。At that time, 4DMT shared plans to discontinue early-stage rare disease programs evaluating 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa. The company also indicated it would pause new preclinical investments, projecting that these adjustments would enable it to fund operations into 2028..当时，4DMT分享了计划，将终止早期罕见病项目，包括针对脉络膜缺失症评估4D-110和针对X连锁视网膜色素变性评估4D-125的项目。该公司还表示将暂停新的临床前投资，预计这些调整将使其能够为运营提供资金直至2028年。Progress in 4FRONT Phase 3 Trials of 4D-1504D-150在4FRONT第三阶段试验中的进展4DMT highlighted that enrollment and site activation for 4FRONT-1, the North American phase 3 trial of 4D-150 in wet AMD, have surpassed initial expectations. The first patient in 4FRONT-1 was enrolled in March 2025, and topline data are now anticipated in the first half of 2027—earlier than the initial forecast of late 2027..4DMT 强调，湿性 AMD 的 4D-150 北美 III 期试验 4FRONT-1 的受试者招募和试验站点启动已超出最初预期。4FRONT-1 的首例患者于 2025 年 3 月入组，目前预计将在 2027 年上半年获得初步数据——比最初的 2027 年底预测提前。Additionally, 4FRONT-2, the global phase 3 trial of 4D-150 in wet AMD, was initiated in June 2025 ahead of schedule. This study mirrors the design of 4FRONT-1 but will enroll both treatment-naïve patients and recently diagnosed, treatment-experienced individuals. Topline results from 4FRONT-2 are expected in the second half of 2027..此外，4D-150用于湿性AMD的全球三期试验4FRONT-2已于2025年6月提前启动。该研究的设计与4FRONT-1相似，但将同时纳入未曾接受治疗的患者和近期确诊、有治疗经验的人士。4FRONT-2的初步结果预计将在2027年下半年公布。Workforce Reduction to Offset Costs and Reallocate Resources裁员以抵消成本并重新分配资源As part of its operational transition, 4DMT plans to reduce its workforce by approximately 25% in July 2025, primarily impacting early-stage research, development, and related support functions. This reduction is expected to deliver about $15 million in annual cash compensation cost savings, helping offset increased expenses from the accelerated phase 3 timelines and BLA work..作为其运营过渡的一部分，4DMT 计划在 2025 年 7 月裁员约 25%，主要影响早期研究、开发及相关支持职能。此次裁员预计每年可节省约 1500 万美元的现金薪酬成本，有助于抵消因加速第三阶段时间表和 BLA 工作带来的支出增加。Leadership Comments on Strategic Shift领导层对战略转变的评论David Kirn, MD, co-founder and CEO, and Dhaval Desai, chief development officer of 4DMT, shared insights into the company’s direction in a press release.4DMT联合创始人兼首席执行官David Kirn医学博士以及首席开发官Dhaval Desai在新闻稿中分享了公司发展方向的见解。“We are thrilled with the strong interest in 4D-150 from investigators and patients in both 4FRONT phase 3 studies, reflecting their belief in the phase 1/2 data demonstrating the tolerability and robust, durable clinical activity of this potential foundational backbone therapy for retinal vascular diseases,” said Desai..“我们对4D-150在两项4FRONT三期研究中引起的研究者和患者的浓厚兴趣感到非常兴奋，这反映了他们对一期/二期数据的信任，这些数据展示了这种潜在的基础骨干疗法在视网膜血管疾病中的耐受性以及强大且持久的临床活性，”Desai表示。Kirn added, “We have aligned our resources to deliver on our mission of bringing transformative and durable genetic medicines to millions of patients in need, with a focus on 4D-150 for wet AMD, in our ongoing transition to becoming a commercial company. I want to express my deep gratitude and respect for the talented colleagues whose work has been critical to 4DMT’s success to date, who we thank sincerely for their dedication to and passion for our mission.”.柯恩补充道：“我们已经整合了资源，以实现我们为数百万有需要的患者提供变革性且持久的基因药物的使命，并在我们向商业化公司转型的过程中，重点关注用于湿性AMD的4D-150。我要对我们才华横溢的同事们表达深深的感激与敬意，他们的工作对4DMT迄今为止的成功至关重要，我们衷心感谢他们对我们的使命所付出的奉献和热情。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549546558","isCrawlerRequest":true}